

Thomas D Barbour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4124434/publications.pdf>

Version: 2024-02-01

23
papers

800
citations

840585

11
h-index

713332

21
g-index

24
all docs

24
docs citations

24
times ranked

1026
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. <i>Kidney International Reports</i> , 2021, 6, 1603-1613.	0.4	29
2	Proliferative Glomerulonephritis With Fibrils, Monoclonal κ Light Chain, and C3 Deposits. <i>American Journal of Kidney Diseases</i> , 2021, 78, 459-463.	2.1	2
3	SO054 ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	2
4	Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association?. <i>BMC Nephrology</i> , 2020, 21, 293.	0.8	2
5	Cat-Scratch Disease Masquerading as C3 Glomerulonephritis. <i>Kidney International Reports</i> , 2020, 5, 2388-2392.	0.4	1
6	Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. <i>Nephrology</i> , 2020, 25, 683-690.	0.7	6
7	<p>Management of refractory lupus nephritis: challenges and solutions</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 179-188.	0.8	17
8	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. <i>Internal Medicine Journal</i> , 2018, 48, 624-636.	0.5	26
9	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. <i>Nephrology</i> , 2018, 23, 507-517.	0.7	21
10	Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause. <i>Scientific Reports</i> , 2018, 8, 9021.	1.6	10
11	Durable remission of C3 glomerulonephritis with mycophenolate mofetil. <i>Nephrology</i> , 2017, 22, 36-39.	0.7	2
12	The perfect storm. <i>Kidney International</i> , 2017, 92, 267.	2.6	3
13	Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy. <i>Kidney International</i> , 2016, 89, 823-832.	2.6	7
14	Update on C3 glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 717-725.	0.4	52
15	Atypical aHUS: State of the art. <i>Molecular Immunology</i> , 2015, 67, 31-42.	1.0	236
16	An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. <i>Kidney International</i> , 2015, 88, 1314-1322.	2.6	58
17	Antiphospholipid syndrome in renal transplantation. <i>Nephrology</i> , 2014, 19, 177-185.	0.7	21
18	Disorders of complement regulation. <i>Drug Discovery Today: Disease Models</i> , 2014, 11, 29-35.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Dense Deposit Disease and C3 Glomerulopathy. <i>Seminars in Nephrology</i> , 2013, 33, 493-507.	0.6	57
20	Recent insights into C3 glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1685-1693.	0.4	70
21	Thrombotic microangiopathy and associated renal disorders. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2673-2685.	0.4	168
22	Simultaneous necrotizing glomerulonephritis and Hodgkin's lymphoma: a case report and review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3403-3408.	0.4	1
23	Efavirenz-associated podocyte damage. <i>Aids</i> , 2007, 21, 257-258.	1.0	9